media – Page 274 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50% of DCIS patients may develop an invasive stage of cancer, yet identifying which tumors will progress is still a challenge due to unknown biomarkers. Current diagnostic practices include multiplexed staining or single-cell RNA sequencing to determine DCIS stages in tissue samples, but these methods are costly and not widely used. This has led to potential overtreatment of patients with DCIS. Now, a new artificial intelligence (AI) model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images. The model developed by an interdisciplinary team of researchers from MIT (Cambridge, MA, USA) and ETH Zurich (Zurich, Switzerland) was trained and tested using one of the largest datasets of its kind ...
- Source: https://www.labmedica.com/pathology/articles/294801919/ai-model-identifies-breast-tumor-stages-likely-to-progress-to-invasive-cancer.html
- 226
- July 26, 2024
Handheld Device Puts Power of Lab-Based Diagnostic Testing in the Palm of Your Hand

Many common tests for infectious diseases work by detecting either antigens related to the virus or antibodies created in response to the infection. These tests, which now include widely used COVID-19 rapid antigen tests, offer the advantages of speed and broad availability. However, polymerase chain reaction (PCR) tests still surpass these in terms of accuracy, reaching nearly 100%. PCR tests, considered the gold standard in infectious disease diagnostics, excel because they detect a pathogen’s genetic material like RNA directly. This capability increases specificity, reducing the likelihood of false positives. PCR can also amplify minimal amounts of genetic material, allowing it to detect infections at very low levels. Yet, PCR requires specialized skills and expensive equipment, which limits its availability, particularly in low-resource settings. Researchers at the University of Connecticut (Storrs, CT, USA) have now developed a platform technology that incorporates PCR-like capabilities within a handheld device, as detailed in ...
- Source: https://www.labmedica.com/molecular-diagnostics/articles/294801920/handheld-device-puts-power-of-lab-based-diagnostic-testing-in-the-palm-of-your-hand.html
- 593
- July 26, 2024
【EXPERT Q&A】What qualifications do foreign trade enterprises need to agent drug export?

Drugdu.com expert’s response: The qualifications required for foreign trade enterprises to act as agents for pharmaceutical exports primarily encompass the following aspects: I. Basic Qualifications 1.Foreign Trade Management Right: Foreign trade companies must possess general foreign trade import and export management rights, which serve as the fundamental prerequisite for acting as agents for pharmaceutical exports. This right permits the company to engage in or act as an agent for the import and export of various goods and technologies, except for those commodities and technologies whose import and export are restricted or prohibited by the state. 2.Registration: Foreign trade companies need to register with relevant government departments. For instance, they must register with the Ministry of Foreign Trade and Economic Cooperation to obtain import and export qualifications and with the Entry-Exit Inspection and Quarantine Bureau to acquire a quarantine registration code. These registrations are crucial steps to ensure compliance with regulations ...
- Source: drugdu
- 369
- July 26, 2024
Pharmapack

Organiser： Informa Exhibitions Group Time：January 22-23, 2025 address：1, place de la Porte de Versailles, 75015 Paris, France Exhibition hall：Paris Expo Porte de Versailles Product range: Ⅰ. Design and innovation of drug delivery systems, raw materials (aluminum, cardboard, plastic, and glass) Ⅱ. Transformers, packaging machinery, production equipment, automation and assembly line systems, product and packaging design services, parts and components for thermoforming packaging Ⅲ. Aerosols, ampoules, sprays, blisters, medical devices, pharmaceutical packaging, vials, unit doses Ⅳ. Labels and markings, medical pumps, medical bags, syringes, pen injectors, reconstitution systems, tubes, and more Ⅴ. Pharmaceutical subcontractors, printing and labeling, instruction manuals, brochures, sterilization technologies and services, control, tracking and anti-counterfeiting, transportation materials and services About Pharmapack： Pharmapack, the Pharmaceutical Packaging Exhibition in Paris, France, is the largest and most authoritative pharmaceutical packaging exhibition in the country. It brings together global leading industry designers, pharmaceutical manufacturers, drug packaging, and delivery system suppliers. It ...
- Source: drugdu
- 378
- July 26, 2024
Portable PCR Platform to Detect Multiple Pathogenic Bacteria Targets and Antibiotic Susceptibility at POC

Gonorrhea, the second most reported bacterial sexually transmitted infection (STI), affected approximately 82 million people globally in 2020. The incidence is higher in low and middle-income countries where the burden of drug resistance is most pronounced. Gonorrhea can lead to severe health complications such as pelvic inflammatory disease, chronic pelvic pain, and infertility. Since not all patients show symptoms, the true burden of the disease is likely much greater than reported cases suggest. To combat this, rapid and advanced diagnostics are crucial for detecting drug-resistant bacterial infections early and guiding effective treatment. Now, a portable PCR platform with high multiplexing capabilities is being developed to identify multiple pathogenic bacterial targets and their antibiotic susceptibility, thus aiding in point-of-care treatment decisions. Prompt Diagnostics (Baltimore, MD, USA) has been awarded USD 1 million by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X, Boston, MA, USA) to further the development of its portable PCR ...
- Source: drugdu
- 307
- July 25, 2024
Protein Signatures in Blood Can Predict Risk of Developing More Than 60 Diseases

Measuring specific proteins to diagnose conditions like heart attacks, where troponin is tested, is a well-established clinical practice. Now, new research highlights the broader potential of protein measurements from a small blood sample to predict a variety of diseases. In the research, published in Nature Medicine, which was carried out as part of an international partnership involving Queen Mary University of London (London, UK), the investigators used data from the UK Biobank Pharma Proteomics Project (UKB-PPP). This project represents the largest proteomic study to date, analyzing around 3,000 plasma proteins from over 40,000 randomly selected UK Biobank participants. These protein measurements are linked to detailed electronic health records. The researchers applied sophisticated analytical techniques to identify a specific ‘signature’ of 5 to 20 key proteins for predicting each disease. They discovered that these protein ‘signatures’ can predict the onset of 67 different diseases, including multiple myeloma, non-Hodgkin lymphoma, motor neuron ...
- Source: drugdu
- 299
- July 25, 2024
FDA Approves Merz Aesthetics’ Xeomin for Simultaneous Treatment of Upper Facial Lines

By Don Tracy, Associate Editor The new approval expands Xeomin’s indications to include horizontal forehead lines and lateral canthal lines.The FDA has approved Merz Aesthetics’ Xeomin (incobotulinumtoxinA) as the first and only neurotoxin in the United States indicated for the simultaneous treatment of upper facial lines, including forehead lines, frown lines, and crow’s feet. According to the company, to improve the appearance of moderate to severe upper facial lines, the recommended dose is 20 units for glabellar frown lines, 20 units for horizontal forehead lines, and 24 units for the crow’s feet for a total of 64 units. Xeomin was initially approved by the FDA in 2011 for temporary improvement in the appearance of moderate to severe glabellar lines and frown lines.1 “Xeomin is the first and only FDA-approved neurotoxin for the simultaneous treatment of upper facial lines (forehead lines, frown lines and crow’s feet lines),” said Samantha Kerr, PhD, ...
- Source: drugdu
- 517
- July 25, 2024
Vivacelle Bio Launches Phase III Clinical Trial for VBI-S to Treat Hypovolemic Septic Shock

By Don Tracy, Associate Editor The trial is expected to include 40 patients across the United States who haven’t responded adequately to standard hypovolemic septic shock treatments and are on vasopressors. Vivacelle Bio has launched a Phase III clinical trial for its leading therapeutic candidate, VBI-S, designed to treat hypovolemic septic shock. According to the company, the trial will be conducted across seven major septic shock treatment centers in the United States, which include some of the biggest septic shock treatment centers in the country. Investigators seek to compare VBI-S and standard of care (SOC) to SOC alone in a 1:1 ratio. “Initiation of our Phase III trial is a significant achievement for our team following years of dedicated work developing our phospholipid nanoparticle technology platform,” said Harven DeShield, PhD, JD, MSc, CEO, Vivacelle, in a press release. “Based on our excellent Phase II results, and the positive interaction with ...
- Source: drugdu
- 261
- July 25, 2024
Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection by SINOPHARM Lanzhou Institute of Biological Products Receives Clinical Trial Approval

On July 12, Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection, a Class I new drug independently developed by SINOPHARM Lanzhou Institute of Biological Products, was granted a clinical trial approval notice by the State Drug Administration. Tetanus is a persistent tonic contraction and paroxysmal spasm of skeletal muscles throughout the body caused by the invasion of Clostridium tetani through a break in the skin or mucous membrane. Globally, the morbidity and mortality rate of tetanus is 30% to 50% after onset of the disease, even with aggressive treatment; in the absence of medical intervention, the mortality rate approaches 100%. According to the World Health Organization, tetanus currently kills about 1 million people worldwide each year. The term “tetanus shot” is short for tetanus passive immunization agent, which is usually isolated from healthy human or horse blood that has been vaccinated against tetanus. Tetanus injections are often needed in cases of ...
- Source: drugdu
- 338
- July 25, 2024
ANKE Bio received clinical approval for another therapeutic mRNA vaccine

ANKE Bio (Group) Co., Ltd. and Hefei Alfana Biotechnology Co., Ltd. jointly developed a Class 1 new drug that received clinical approval from the Drug Administration (Drug Clinical Trial Approval Notification: 2024LP01608), with an indication for the treatment of cervical intraepithelial neoplasia. It is reported that this is the first therapeutic mRNA vaccine approved for clinical use in cervical intraepithelial neoplasia in China. Pre-cancerous lesions and their eventual malignant changes caused by viral infections are a serious threat to people’s lives and health. Globally, approximately 600 million people are infected with human papillomavirus (HPV), in addition to approximately 250 million people infected with hepatitis B virus (HBV), and 71 million people infected with hepatitis C virus (HCV). People infected with each of these viruses face a potential cancer risk. For example, approximately 30 million women are diagnosed each year with cervical intraepithelial neoplasia (CIN), an important precursor to cervical cancer. ...
- Source: drugdu
- 384
- July 25, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.